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Abstract 
Background: Inherited fibrinogen deficiencies are classified into two 
categories: quantitative (including a fibrinogenemia and hypofibrinogenemia) 
and qualitative (including dysfibrinogenemia). Any mutation in fibrinogen 
genes accounts for one of these disorders.  
Case Report: This article reports an Iranian family with dysfibrinogenemia 
without any clinical signs accidentally diagnosed by routine coagulation tests 
with slightly elevated PT and APTT a few years ago. For determination of the 
disease which causing genetic aberration in fibrinogen genes, DNA 
sequencing of three hot spots of these genes (i.e. exon 2 of FGA, exon 2 of 
FGB and exon 8 of FGG) was performed. Analysis of sequencing results 
revealed a heterozygous missense mutation c.901 C>T (Arg275Cys) in exon 
8 of FGG in mother and children. No mutation was detected in father’s 
sample. Fibrinogen with this mutation is known as Tokyo II.  
Conclusion: γArg275Cys is a heterozygous mutation that impairs the 
function of fibrinogen and has been solely reported in dysfibrinogenemic 
patients. Clinical findings in this family (no history of bleeding and 
thrombosis) were compatible with molecular results, because fibrinogen 
Tokyo II does not have a thrombotic or hemorrhagic nature and lack of 
clinical signs in this family is not unexpected. 
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Introduction 
In hepatocytes, transcription of three clustered 
genes of FGA, FGB and FGG leads to production of 
three polypeptide chains Aα, Bβ, and γ, eventually 
causes fibrinogen formation. This factor is secreted to 
blood with normal plasma level of 1.5-3.5 gr/L (1). 
Inherited fibrinogen deficiencies are rare bleeding 
disorders (RBDs) that classified into two categories: 
quantitative, including a fibrinogenemia (factor level 
<0.1 gr/L) and hypofibrinogenemia (factor level 0.5-
1.5 gr/L) as well as qualitative, including 
dysfibrinogenemia that is characterized with 
abnormal function of fibrinogen (2). The main goal of 
coagulation cascade is conversion of fibrinogen to 
fibrin polymers and clot formation (1). Mutation in 
one of the fibrinogen genes can account for any of 
these disorders. The most important causative 
mutations of congenital dysfibrinogenemia (CD) have 
been identified in exon 2 of FGA, exon 2 of FGB and 
exon 8 of FGG (3). Here we described the first 
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dysfibrinogenemic Iranian family with γArg275Cys 
mutation bearing fibrinogen Tokyo II which was not 
reported previously in Kermanshah Province. 
Case Presentation 
This study was performed in 2015 and reports 
a family with consanguineous marriage from 
Kermanshah Province, Sahne city of Iran. Mother of 
case was diagnosed as dysfibrinogenemic just during 
routine coagulation tests before caesarian section 16 
years ago. Prolonged prothrombin time (PT) and 
slightly elevated activated partial thromboplastin time 
(APTT) along, with abnormal fibrinogen activity 
measured by Clause method were indicative of 
dysfibrinogenemia. Moreover, lack of liver failure 
symptoms like increased plasma liver enzymes 
excluded acquired form of the disorder. Two sons 
were screened for disease when they were one year 
old and CD was confirmed in them. Table 1 displays 
the results of coagulation tests in this family. As it is 
evident in Table 1, the father was apparently healthy. 
Considering the clinical manifestations, none of the 
members of this family had experienced bleeding 
(such as menorrhagia and postpartum hemorrhage in 
mother, epistaxis, oral cavity bleeding, bleeding after 
dental extraction and hematomas) or thrombosis. 
This study was continued by molecular tests 
for determination of disease causing genetic 
aberration in fibrinogen genes. After receiving the 
consent form and sampling, DNA was extracted from 
whole blood of all family members using DNA 
extraction kit (Blood & Tissue Genomic DNA 
Extraction Miniprep System; Viogene, Taipei, 
Taiwan). After that, DNA was used for amplification 
of hot spots CD variation according to updated 
fibrinogen mutation GEHT web site 
(www.geht.org/databaseang/fibrinogen), including 
exon 2 of FGA, exon 2 of FGB and exon 8 of FGG. 
The primers used for PCR amplification and 
sequencing of these three exons as well as PCR 
information are shown in Table 2.  After purification 
of PCR products by agarose gel extraction, they were 
cycle sequenced by forward and reverse primers. 
Interpretation of cycle sequencing results by 
Mutation Surveyor version 3.3 and Chromas version 
2.4.3 software revealed a heterozygous substitution of 
C>T at position 901 of cDNA (c.901 C>T) in exon 8 
of FGG, which leads to replacement of arginine by 
cysteine at position 275 of mature gamma chain 
(position 301 in immature form). This missense 
mutation is a known disease causing variant 
“rs12913087” for CD. The fibrinogen bearing this 
mutation is named Tokyo II (Other names: Osaka 2 
/Tochigi 1 /Moricka 1). As expected, this variation 
was not found in the sample taken from healthy father 
as expected (Figure 1). 
Discussion 
We have reported the first Iranian family with 
fibrinogen Tokyo II. Despite the high prevalence of 
fibrinogen disorders in Iran in comparison to other 
countries, molecular investigation of this disorder is 
uncommon in this province.  
According to World Federation of Hemophilia 
(WFH) in 2013, Iran has highest number of patients 
with inherited fibrinogen disorders (5).  Because of the 
presence of some cases with asymptomatic 
dysfibrinogenemia (like this family), a larger number 
of patients is estimated in communities. 
Arg275Cys mutation involves a C-terminal 
region of gamma chain, which is crucial for end to 
end alignment at fibrin monomers. So, this amino acid 
exchange is thought to be associated with abnormal 
interaction in fibrin monomers (6). 
In comparison to known thrombotic mutation 
Arg573Cys in alpha chain of fibrinogen in CD 
patients, Arg275Cys in gamma chain does not involve 
Table 1: Coagulation test results in all the family 
members. 




Father 12 30.5 2.6 
Mother 17 38 0.45 
Son 1 17.6 38.3 0.47 
Son 2 16.7 40.6 0.6 
Prothrombin Time/Normal range: 11.8 -14.6 second 
Activated Partial Thromboplastin Time/Normal range: 30-
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thrombotic and bleeding effects (7). 
Two mutations of Arg275Cys and Arg275His 
were identified in 17% of dysfibrinogenemic patients 
from UK (8). Also, more comprehensive study at 
Finland on 101 affected subjects reported that 
Arg275Cys mutation is the most common cause of 
dysfibrinogenemia with prevalence of 32.7% (9). 
Nevertheless, another study has indicated Arg16Cys 
mutation in alpha chain as the main variation of hot 
spot in dysfibrinogenemia (10). So, mutations 
detected incase reports or case series with 
dysfibrinogenemia can provide more data for 
resolution of these conflicts. 
The presence of two affected sons in a family 
with healthy father and carrier mother (heterozygous 
mutation) may be justified by autosomal dominant 
inheritance pattern of CD. So far, almost all of the 
mutations detected in CD subjects have been 
heterozygous. 
Conclusion 
Arg275Cys is a heterozygous mutation that 
impairs the function of fibrinogen and has been solely 
reported in dysfibrinogenemic patients. Clinical 
findings in this family (no history of bleeding and 
thrombosis) were compatible with molecular results 
since Tokyo II fibrinogen does not have thrombotic 
and hemorrhagic nature and lack of clinical signs in 
this family is not unexpected. 
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Fig. 1.  Detection of Arg275Cys mutation of γ-
fibrinogen in three affected members. Heterozygous 
mutation was shown in codon 901(CGC to TGC) in 
mother and her affected sons. 
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